MapLight plans sale of 36,284 common shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Anatol Kreitzer filed a notice covering a planned sale of 36,284 shares of MapLight voting common stock of MapLight Therapeutics, Inc., to be sold through Morgan Stanley Smith Barney LLC on or about July 15, 2026 on Nasdaq, with an aggregate market value of $1,375,526.00.
The notice also lists prior sales of MapLight voting common stock in the past three months: 3,316 shares for $88,239.00 on April 15, 2026, and 45,422 shares for $1,347,066.00 on April 27, 2026. Shares outstanding are reported as 42,618,165.
Key Figures
Key Terms
voting common stock financial
Restricted stock unit settlement financial
Securities Sold During The Past 3 Months regulatory
Nasdaq financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does MapLight Therapeutics (MPLT) disclose in this 144/A filing?
What prior MPLT stock sales by Anatol Kreitzer are listed in the last three months?
AI-generated analysis. How Rhea-AI works. Not financial advice.